Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis

Surprisingly similar impact on leukocyte infiltration

shintaro nakao, Souska Zandi, Nuria Lara-Castillo, Mahdi Taher, Tatsuro Ishibashi, Ali Hafezi-Moghadam

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose. The current treatments against inflammatory angiogenesis are steroids and anti-VEGF-A, such as dexamethasone and bevacizumab, respectively. However, the therapeutic windows for dexamethasone and bevacizumab against inflammatory angiogenesis are unknown. Methods. To investigate the therapeutic windows for dexamethasone and bevacizumab, we used the corneal pocket assay. IL-1β pellets were implanted in corneas of BALB/c mice that were then treated with dexamethasone or bevacizumab at different time points. Angiogenesis (area, number of vessels, and sprouting) was quantitated at various time points after implantation. Nuclear Factor-κB (NF-κB) signaling and leukocyte accumulation in inflammatory angiogenesis were examined by Western blotting, by immunohistochemistry, and in the authors' novel leukocyte transmigration assay. Results. Dexamethasone inhibited IL-1β-induced angiogenesis when treatment started 4 days after IL-1β implantation, while bevacizumab only inhibited angiogenesis by day 2 after implantation. Both bevacizumab and dexamethasone inhibited angiogenic sprouting. Interestingly, bevacizumab did not affect NF-κB activation, which is one of the main signaling targets for steroid action. The authors' new imaging approach revealed that bevacizumab and steroid treatment blocked leukocyte infiltration into implanted corneas. Conclusions. VEGF-A inhibition affected angiogenic sprouting, while it was not effective against matured vessels. Both dexamethasone and bevacizumab inhibited leukocyte transmigration from angiogenic vessels; however, dexamethasone had a larger therapeutic window. These insights improve the treatment strategy in angiogenic disorders.

Original languageEnglish
Pages (from-to)3296-3302
Number of pages7
JournalInvestigative Ophthalmology and Visual Science
Volume53
Issue number7
DOIs
Publication statusPublished - Jan 1 2012

Fingerprint

Vascular Endothelial Growth Factor A
Dexamethasone
Leukocytes
Steroids
Interleukin-1
Therapeutics
Cornea
Bevacizumab
Western Blotting
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis : Surprisingly similar impact on leukocyte infiltration. / nakao, shintaro; Zandi, Souska; Lara-Castillo, Nuria; Taher, Mahdi; Ishibashi, Tatsuro; Hafezi-Moghadam, Ali.

In: Investigative Ophthalmology and Visual Science, Vol. 53, No. 7, 01.01.2012, p. 3296-3302.

Research output: Contribution to journalArticle

@article{d8f415227d4a4ebb8aead173a02cdfaf,
title = "Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: Surprisingly similar impact on leukocyte infiltration",
abstract = "Purpose. The current treatments against inflammatory angiogenesis are steroids and anti-VEGF-A, such as dexamethasone and bevacizumab, respectively. However, the therapeutic windows for dexamethasone and bevacizumab against inflammatory angiogenesis are unknown. Methods. To investigate the therapeutic windows for dexamethasone and bevacizumab, we used the corneal pocket assay. IL-1β pellets were implanted in corneas of BALB/c mice that were then treated with dexamethasone or bevacizumab at different time points. Angiogenesis (area, number of vessels, and sprouting) was quantitated at various time points after implantation. Nuclear Factor-κB (NF-κB) signaling and leukocyte accumulation in inflammatory angiogenesis were examined by Western blotting, by immunohistochemistry, and in the authors' novel leukocyte transmigration assay. Results. Dexamethasone inhibited IL-1β-induced angiogenesis when treatment started 4 days after IL-1β implantation, while bevacizumab only inhibited angiogenesis by day 2 after implantation. Both bevacizumab and dexamethasone inhibited angiogenic sprouting. Interestingly, bevacizumab did not affect NF-κB activation, which is one of the main signaling targets for steroid action. The authors' new imaging approach revealed that bevacizumab and steroid treatment blocked leukocyte infiltration into implanted corneas. Conclusions. VEGF-A inhibition affected angiogenic sprouting, while it was not effective against matured vessels. Both dexamethasone and bevacizumab inhibited leukocyte transmigration from angiogenic vessels; however, dexamethasone had a larger therapeutic window. These insights improve the treatment strategy in angiogenic disorders.",
author = "shintaro nakao and Souska Zandi and Nuria Lara-Castillo and Mahdi Taher and Tatsuro Ishibashi and Ali Hafezi-Moghadam",
year = "2012",
month = "1",
day = "1",
doi = "10.1167/iovs.11-8114",
language = "English",
volume = "53",
pages = "3296--3302",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "7",

}

TY - JOUR

T1 - Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis

T2 - Surprisingly similar impact on leukocyte infiltration

AU - nakao, shintaro

AU - Zandi, Souska

AU - Lara-Castillo, Nuria

AU - Taher, Mahdi

AU - Ishibashi, Tatsuro

AU - Hafezi-Moghadam, Ali

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose. The current treatments against inflammatory angiogenesis are steroids and anti-VEGF-A, such as dexamethasone and bevacizumab, respectively. However, the therapeutic windows for dexamethasone and bevacizumab against inflammatory angiogenesis are unknown. Methods. To investigate the therapeutic windows for dexamethasone and bevacizumab, we used the corneal pocket assay. IL-1β pellets were implanted in corneas of BALB/c mice that were then treated with dexamethasone or bevacizumab at different time points. Angiogenesis (area, number of vessels, and sprouting) was quantitated at various time points after implantation. Nuclear Factor-κB (NF-κB) signaling and leukocyte accumulation in inflammatory angiogenesis were examined by Western blotting, by immunohistochemistry, and in the authors' novel leukocyte transmigration assay. Results. Dexamethasone inhibited IL-1β-induced angiogenesis when treatment started 4 days after IL-1β implantation, while bevacizumab only inhibited angiogenesis by day 2 after implantation. Both bevacizumab and dexamethasone inhibited angiogenic sprouting. Interestingly, bevacizumab did not affect NF-κB activation, which is one of the main signaling targets for steroid action. The authors' new imaging approach revealed that bevacizumab and steroid treatment blocked leukocyte infiltration into implanted corneas. Conclusions. VEGF-A inhibition affected angiogenic sprouting, while it was not effective against matured vessels. Both dexamethasone and bevacizumab inhibited leukocyte transmigration from angiogenic vessels; however, dexamethasone had a larger therapeutic window. These insights improve the treatment strategy in angiogenic disorders.

AB - Purpose. The current treatments against inflammatory angiogenesis are steroids and anti-VEGF-A, such as dexamethasone and bevacizumab, respectively. However, the therapeutic windows for dexamethasone and bevacizumab against inflammatory angiogenesis are unknown. Methods. To investigate the therapeutic windows for dexamethasone and bevacizumab, we used the corneal pocket assay. IL-1β pellets were implanted in corneas of BALB/c mice that were then treated with dexamethasone or bevacizumab at different time points. Angiogenesis (area, number of vessels, and sprouting) was quantitated at various time points after implantation. Nuclear Factor-κB (NF-κB) signaling and leukocyte accumulation in inflammatory angiogenesis were examined by Western blotting, by immunohistochemistry, and in the authors' novel leukocyte transmigration assay. Results. Dexamethasone inhibited IL-1β-induced angiogenesis when treatment started 4 days after IL-1β implantation, while bevacizumab only inhibited angiogenesis by day 2 after implantation. Both bevacizumab and dexamethasone inhibited angiogenic sprouting. Interestingly, bevacizumab did not affect NF-κB activation, which is one of the main signaling targets for steroid action. The authors' new imaging approach revealed that bevacizumab and steroid treatment blocked leukocyte infiltration into implanted corneas. Conclusions. VEGF-A inhibition affected angiogenic sprouting, while it was not effective against matured vessels. Both dexamethasone and bevacizumab inhibited leukocyte transmigration from angiogenic vessels; however, dexamethasone had a larger therapeutic window. These insights improve the treatment strategy in angiogenic disorders.

UR - http://www.scopus.com/inward/record.url?scp=84861990387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861990387&partnerID=8YFLogxK

U2 - 10.1167/iovs.11-8114

DO - 10.1167/iovs.11-8114

M3 - Article

VL - 53

SP - 3296

EP - 3302

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 7

ER -